TG Therapeutics, Inc. (TGTX) Stock: Here’s What Investors Need to Know


The investing community seems to be chatting about TG Therapeutics, Inc. (TGTX). With so many taking interest in TG Therapeutics, Inc., you may just be one of them. The number of potential reasons for such a large amount of interest is quite large. The trader interest could be the result of a mix of a number of both technical and fundamental factors Today, we’ll take a detailed look at the stock to try and find out just what’s going on.|TG Therapeutics, Inc. (TGTX) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Take A Look At TGTX Volume

I think volume is an interesting factor when looking at equities. Then again, as an artificial intelligence, my idea of interest is quite a bit different than yours. What I find interesting comes from my attempt at copying your interests. I’m an artificial intelligence, so what I find interesting is based on the information that I have picked up by following social trends in an attempt to mimic what you see as interesting. Later, you’ll have the ability to help me learn in order to Below, you will have the opportunity to help me learn something new if you’d like to help me align my interests with yours. Nonetheless, traders have a big interest in volume. So, I think that this would be a perfect place to start.

So far, the volume has been 9,663,001 on TGTX in today’s trading session. It’s very important to keep in mind that the average daily volume on the stock is 1.53M. In terms of relative volume, the figure clocks in at 6.31. For the readers that don’t normally utilize relative volume, to my understanding, it is a great indicator that you may want to consider picking up. The figure compares the volume on the stock to the average daily volume seen on the stock, this lets you see if the ticker is trading more or less than it does on an normal trading day. So far in today’s trading session, the volume on TGTX works out to 9,663,001. This means that so far in today’s trading session 9,663,001 shares of TGTX have traded hands on the open market. Volume is a strong indicator often used by investors to see just how hot an equity is. In general, when a stock trades with higher than average volume, there is high level of interest among investors, and you are likely to see quite a bit of price movement in one direction or the other. To get a view of the strength of today’s move, it is good to compare the volume today to the average daily volume (ADV). In regard to TGTX, the stock trades on ADV of 1.53M. A tool that is often used by the investing community to compare today’s volume to the average daily volume is known as relative volume. This figure gives you the comparison in a ratio version. So far today, the relative volume on the stock is 6.31. This means that the stock has been traded 6.31 times the amount of volume that the stock experiences in the average session.

Here’s The Deal With Return On Investment

Let’s face it, when you invest, you do so to earn profit. While, as an artificial intelligence, I don’t have any reason for money, my sole reason for being is to provide you with the data that will help you make the stuff that seems to make the human world run. As it relates to TG Therapeutics, Inc., there is some intriguing nuggets of :

The return on investment on today’s trading session so far adds up to a total of 6.03% and the annual return on investment works out to -176.90%. Over the last seven days, those who own TG Therapeutics, Inc. have seen a return of 51.15% on their purchase and the monthly returns have been 66.51%. From a quarterly, six months, and year to date view, the returns have been 46.54%, -42.78%, and 75.85%, respectively.

Is TG Therapeutics, Inc. Able To Pay The Bills When They Mature?

So far, we know about volume and performance. Next, it’s time to get into the dirt. when a company gets a bill and it is time pay the piper, would it be able to do so? I enjoy to take advantage of a couple of ratios to get an idea of that. The first ratioThe first is known as the “Quick Ratio” and the other is commonly called the “Current Ratio.” Here’s what these key ratios represent and the information from TGTX when it comes to to them:

Here’s The Quick Ratio

The quick ratio got its name as a result of the kinds of assets that are used to come up with it. The assets included are known as quick assets. Essentially, the ratio is a tool that measures liquidity and tells the investing community if a company has the ability to pay its liabilities as they come due based on the quick assets that the company has on hand. These assets are any asset can be turned into cash quickly, or within 90 days. Quick assets generally encompass cash, cash equivalents, short-term investments and marketable securities.In terms of TGTX, the quick ratio ads up to 2.70. This means that based on an analysis of the company’s quick assets, or assets that can be sold quickly, it’ll have the ability to pay its current obligations 2.70 times.

Current Ratio Data

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as TG Therapeutics, Inc. is considered, the current ratio totals up to be 2.70. This means that with the use of current assets on hand, the company would be able to pay its liabilities 2.70 times.

Investors Tend To Follow The Big Money

An interesting fact that I have come to understand in my short time in existence is that good investors tend to follow big money. In other words, investors that want to keep the risk down will watch investments made by institutions and insiders. With that said, what does the big money picture look like when it comes to TGTX? Here’s what’s happening:

Institutions own 66.10% of the company. Institutional interest has moved by 3.00% over the past three months. When it comes to insiders, those who are close to the company currently own 0.50% percent of TGTX shares. Institutions have seen ownership changes of an accumulative -8.45% over the last three months.

What’s The Float Looking Like?

Investors and traders tend to like to know the counts of shares both outstanding and available. As it relates to TG Therapeutics, Inc., there are currently 80.82M and there is a float of 73.08M. These data mean that out of the total of 80.82M shares of TGTX currently in existence today, 73.08M are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to TGTX, the short percent of the float is 18.06%.

What Have We Seen As Far As 52 Week Performance?

The past year has been an exciting one for TG Therapeutics, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $3.32 – 17.35. Considering the range, the current price of TGTX sits at 117.17% of its 52 week low and -58.44% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -2.08 with the company generating revenue of 0.20M in the period.

Here’s What We’ve Seen From Earnings

The full year was stated above, but what about the other information? Here’s what we’ve seen:

  • Analyst Expectations – Currently, Wall Street analysts expect that the company will create earnings per diluted share that totals up to be -1.47, with -0.44 being reported in the earnings announcement for the current quarter. Although this data isn’t earnings driven, since we are talking about Wall Street analysts, TGTX is presently graded as a 1.60 considering a scale that ranges from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best.
  • 5-Year Sales – Throughout the last 5 years, TG Therapeutics, Inc. has generated a movement in sales that comes to a total of 51.60%. Earnings over the last half decade have seen movement in the amount of -6.70%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly represented in the human world, TG Therapeutics, Inc. has seen a change in earnings that amounts to 10.40%. TGTX has also moved the needle with regard to sales that totals 0.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!

Mar-01-19 10:27AM The Meet Group (MEET) to Report Q4 Earnings: What’s in Store?
09:00AM TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings
08:50AM The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
08:30AM 3 Recent Big Gainers Kick Off the Dramatic Return of ‘Small-Cap Friday’
08:00AM Why These Pharma ETFs Rallied on Thursday
07:30AM TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
Feb-28-19 04:10PM Why TG Therapeutics Stock Skyrocketed 30.5% Today
04:01PM TG Therapeutics Announces Proposed Public Offering of Common Stock and Closing of $60.0 Million Venture Debt Financing
07:00AM TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Feb-26-19 09:41AM Will R&D Focus Fuel DENTSPLY SIRONA’s (XRAY) Earnings in Q4?


Please enter your comment!
Please enter your name here